The mid-stage Nash pipeline plays host to mechanisms both evidence-backed and unproven, with plenty of data on the horizon.
Biogen’s acquisition of rare neurological disease player Reata provides a much needed near-term sales lift, but at a price.
But supply problems are getting worse.
Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
With a focus on France and Germany, the company builder is also closing in on its final two targets.